AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04329195
Drug: 2: continuation of RAS blocker therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuation of RAS blocker therapy
Trial: NCT00525759
Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
Trial: NCT00525759
Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
Trial: NCT01718873
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
Trial: NCT01075282
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02217267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01365663
Drug: SPC4955
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Weekly SC injections
Trial: NCT01365663
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Weekly SC injections
Trial: NCT01289015
Drug: NAFT-600 ( naftin 2 % gel )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical; applied once daily for two weeks
Trial: NCT01289015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical; applied once daily for two weeks
Trial: NCT00649532
Drug: Zofran® Tablets 24 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24mg, single dose fasting
Trial: NCT00283595
Drug: Placebo for Recombinant Human Growth Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
Trial: NCT02961556
Drug: AJG555
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 to 6 sachets daily per participants' age and conditions.
Trial: NCT00290433
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycle 1: 300 mg/m\^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
Trial: NCT00290433
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycle 1 and 2: 200 mg/m\^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m\^2 IV Over 22 Hours on Day 1.
Trial: NCT04294823
Drug: Nexium Pill
RxNorm normalized name: Nexium Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast Nexium mups 40 mg will be discontinued after Day 28.
Trial: NCT00003470
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT01019421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on treatment to donepezil
Trial: NCT00701675
Drug: Placebo 50 or 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg or 100mg matching placebo
Trial: NCT01660932
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01356914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
Trial: NCT02796378
Drug: Training+Simvastatin+Q10-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
Trial: NCT02796378
Drug: Training+Simvastatin-placebo+Q10-placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
Trial: NCT02796378
Drug: Training+Simvastatin+Q10
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
Trial: NCT00669721
Drug: law molecular weigth heparin
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
Trial: NCT00669721
Drug: unfractioned heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
Trial: NCT04304209
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration
Trial: NCT00171288
Drug: fluvastatin, ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05386069
Drug: NOMO Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard weight-based ketamine bolus (0.5 mg/kg) at procedure start, no Opioid rescue medications
Trial: NCT02967029
Drug: Remifentanil Hydrochloride
RxNorm normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the influence of remifentanyl as a hypotensive agent on rSO2
Trial: NCT02071160
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
Trial: NCT00686933
Drug: ABT-089
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take up to 80 mg daily for 24 months
Trial: NCT01879345
Drug: BIA 2-093 - 1800 mg (Group 1)
RxNorm normalized name: meningococcal group B vaccine 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets of BIA 2-093
Trial: NCT01879345
Drug: BIA 2-093 - 2400 mg (Group 2)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets of BIA 2-093 600 mg
Trial: NCT01879345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets
Trial: NCT01965301
Drug: BP1.5375 suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT01965301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT02929264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, single dose
Trial: NCT00239876
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02876887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01814514
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02512588
Drug: BTD-001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02512588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01058096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
Trial: NCT02870361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00106886
Drug: Folic acid, vitamin B6 and B12 or placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03948828
Drug: GnRHa combained with reverse addition therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative patients were treated with GnRHa combined with reverse addition treatment.
Trial: NCT02019329
Drug: RO5545965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily administration from Days 1-12
Trial: NCT00290966
Drug: XRP6976
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03038425
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
Trial: NCT01849770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00467454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT00973076
Drug: AZD8055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, orally administered, twice daily
Trial: NCT04173429
Drug: Nadroparin calcium, warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Trial: NCT01031927
Drug: N-methyl glycine
RxNorm normalized name: N-methyl-pyrrolidone
DrugBank: Methyl pyrrolidone (DB12521)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
Trial: NCT00953901
Drug: Fresh Frozen Plasma Transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01154790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects: study drug 2 subjects: placebo
Trial: NCT01724658
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo orally twice a week with progynova 1 mg oral daily
Trial: NCT01154790
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 subjects: study drug 2 subjects: placebo
Trial: NCT03604965
Drug: GP+CCRT
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
Trial: NCT03604965
Drug: TPF+CCRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
Trial: NCT04577443
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To investigate the role of adenosine on cerebral hemodynamic and headache in healthy volunteers and migraine patients
Trial: NCT00830258
Drug: Pravastatin sodium 80 mg tablets
RxNorm normalized name: pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 80 mg
Trial: NCT03595202
Drug: TS-143
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
Trial: NCT03595202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
Trial: NCT01934036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
Trial: NCT00401479
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02329288
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04060836
Drug: Recombinant Coagulation Factor VIII Injection
RxNorm normalized name: coagulation factor VIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
Trial: NCT01022580
Drug: Infasurf surfactant (ONY, Inc.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
Trial: NCT01022580
Drug: Sham (No Treatment)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.
Trial: NCT02844114
Drug: Ganoderma lucidum spore
RxNorm normalized name: Ganoderma lucidum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G 300mg, 5 tablets by mouth
Trial: NCT02844114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic tramadol 1500mg tablet
Trial: NCT02844114
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv.30 minutes
Trial: NCT02057835
Drug: Placebo to BI 691751
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to BI 691751
Trial: NCT00541229
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 100 mg \& 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
Trial: NCT02057835
Drug: BI 691751 low dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 691751 low dose 2
Trial: NCT02262299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recieve tablets with placebo
Trial: NCT02525822
Drug: IDP-123 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product: IDP-123 Lotion
Trial: NCT03233854
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03233854
Drug: NKTR-255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02404753
Drug: Adjuvant Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
Trial: NCT00783510
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As prescribed by treating physician
Trial: NCT04434144
Drug: Ivermectin + Doxycycline
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 infection was confirmed by RT PCR in every case. For group A, Ivermectin 200mcg/kg single dose and Doxycycline 100mg BID for 10 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 3rd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
Trial: NCT02525822
Drug: Tazorac Cream, 0.1%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator Product: Tazorac Cream, 0.1%
Trial: NCT02525822
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator Product: Vehicle Cream
Trial: NCT03515369
Drug: Babaodan oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
Trial: NCT03515369
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
Trial: NCT00990288
Drug: Hemostatic Matrix
RxNorm normalized name: Floseal Hemostatic Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
Trial: NCT03307915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
Trial: NCT00404183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets BID
Trial: NCT00376493
Drug: metronidazole and doxycycline
RxNorm normalized name: metronidazole and diloxanide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
Trial: NCT00795106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
Trial: NCT01095731
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
Trial: NCT00455312
Drug: Campath 1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
Trial: NCT00455312
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
Trial: NCT02223897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
Trial: NCT01045018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 400 mg
Trial: NCT00834418
Drug: ARAVA™ 20 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 20 mg, single-dose fasting
Trial: NCT01408641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules without topiramate
Trial: NCT04434144
Drug: Hydroxychloroquine + Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 infection was confirmed by RT PCR in every case. For group B, Hydroxychloroquine 400mg first day then 200mg BID + Azithromycin 500mg BID for 5 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 2nd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.
Trial: NCT00443651
Drug: Anti-inflammatory drugs
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).